Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZLIS trial of nebulized aztreonam lysine for prevention of Gram-negative pneumonia in heavily colonized mechanically ventilated adults
2018-003865-32Phase 2Recruiting
- Sponsor
- Alejandro Rodriguez Oviedo � Critical Care Department – Hospital Universitario de Tarragona Joan XXIII
- Start
- Nov 2018
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of aztreonam in Gram-negative pneumonia (2 arms), sponsored by Alejandro Rodriguez Oviedo � Critical Care Department – Hospital Universitario de Tarragona Joan XXIII. Primary endpoints: Microbiological cure at day 5 and Incidence of Gram-negative IVAC. Started Nov 2018; status: recruiting.
02
Drugs
aztreonam
03
Conditions
Gram-negative pneumonia
Beyond the preview
Go deeper on 2018-003865-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003865-32.